High incidence of serum antibodies to Escherichia coli O157 lipopolysaccharide in children with hemolytic-uremic syndrome.
about
Pathogenesis and diagnosis of Shiga toxin-producing Escherichia coli infectionsShiga toxin 2 targets the murine renal collecting duct epitheliumDexamethasone rescues neurovascular unit integrity from cell damage caused by systemic administration of shiga toxin 2 and lipopolysaccharide in mice motor cortexp38 mitogen-activated protein kinase mediates lipopolysaccharide and tumor necrosis factor alpha induction of shiga toxin 2 sensitivity in human umbilical vein endothelial cellsEscherichia coli O157:H7 and O157:H(-) strains that do not produce Shiga toxin: phenotypic and genetic characterization of isolates associated with diarrhea and hemolytic-uremic syndrome.Antibody response to Shiga toxins Stx2 and Stx1 in children with enteropathic hemolytic-uremic syndrome.Pathogenesis of Shiga toxin-associated hemolytic uremic syndrome.Shiga toxin-producing Escherichia coli infection and antibodies against Stx2 and Stx1 in household contacts of children with enteropathic hemolytic-uremic syndromeSaliva IgM and IgA are a sensitive indicator of the humoral immune response to Escherichia coli O157 lipopolysaccharide in children with enteropathic hemolytic uremic syndrome.Characterization of the cytokine immune response in children who have experienced an episode of typical hemolytic-uremic syndrome.Enterohemorrhagic Escherichia coli associated with hemolytic-uremic syndrome in Chilean children.Indirect hemagglutination assay for diagnosis of Escherichia coli O157 infection in patients with hemolytic-uremic syndrome.Molecular detection of sorbitol-fermenting Escherichia coli O157 in patients with hemolytic-uremic syndrome.Sorbitol-fermenting enterohaemorrhagic Escherichia coli O157:H- causes another outbreak of haemolytic uraemic syndrome in children.Escherichia coli Shiga Toxin Mechanisms of Action in Renal Disease.Antibody response to Shiga toxins in Argentinean children with enteropathic hemolytic uremic syndrome at acute and long-term follow-up periods.Shiga toxins and the pathophysiology of hemolytic uremic syndrome in humans and animals.Serodiagnosis using microagglutination assay during the food-poisoning outbreak in Japan caused by consumption of raw beef contaminated with enterohemorrhagic Escherichia coli O111 and O157A prospective study of exposure to verotoxin-producing Escherichia coli among Canadian children with haemolytic uraemic syndrome. The CPKDRC co-investigators.The role of Escherichia coli O 157 infections in the classical (enteropathic) haemolytic uraemic syndrome: results of a Central European, multicentre study.Isolation of enterohemorrhagic Escherichia coli O157 strains from patients with hemolytic-uremic syndrome by using immunomagnetic separation, DNA-based methods, and direct cultureLipopolysaccharide-specific antibodies in plasma and stools of children with Shigella-associated leukemoid reaction and hemolytic-uremic syndromeHuman response to Escherichia coli O157:H7 infection: antibodies to secreted virulence factors.Sensitivities and specificities of premier E. coli O157 and premier EHEC enzyme immunoassays for diagnosis of infection with verotxin (Shiga-like toxin)-producing Escherichia coli. The SYNSORB Pk Study investigatorsDevelopment of a blocking enzyme-linked immunosorbent assay for detection of serum antibodies to O157 antigen of Escherichia coliRole of tumor necrosis factor alpha in disease using a mouse model of Shiga toxin-mediated renal damage.Shiga toxin-producing Escherichia coli: a single-center, 11-year pediatric experience.Preparation, characterization, and immunological properties in mice of Escherichia coli O157 O-specific polysaccharide-protein conjugate vaccinesEscherichia coli O157:H7, other verotoxin-producing E coli and the hemolytic uremic syndrome in childhood.Immune response to verotoxin 1 and 2 in children with Escherichia coli O157:H7 hemorrhagic colitis and classic hemolytic uremic syndrome.Screening for Escherichia coli O157:H7--a nationwide survey of clinical laboratories.A recombinant O-polysaccharide-protein conjugate approach to develop highly specific monoclonal antibodies to Shiga toxin-producing Escherichia coli O157 and O145 serogroupsThe multiplex-PCR-based detection and genotyping of diarrhoeagenic Escherichia coli in diarrhoeal stools.Verotoxin-producing Escherichia coli in culled beef cows grazing rangeland forages.Introduction to the food safety concerns of verotoxin-producing Escherichia coli.Shiga-like toxin inhibition of FLICE-like inhibitory protein expression sensitizes endothelial cells to bacterial lipopolysaccharide-induced apoptosis.The chemoluminescence response of human polymorphonuclear leukocytes to Escherichia coli O and K antigens.Modeling Hemolytic-Uremic Syndrome: In-Depth Characterization of Distinct Murine Models Reflecting Different Features of Human Disease.
P2860
Q24550740-61AD8A80-D8A7-4BEE-8A74-A97411B6EBB3Q24652310-2F5CC0A3-CE19-48FB-BBD0-B277E0F0BDAFQ28534818-BF8C8672-5901-4668-B675-8690ED2DCADEQ30441434-B934E5CB-2AE0-4A10-8628-6D8092650684Q33330315-6CBBDB23-01D4-4137-8CB9-62126C3479A6Q33337454-08F323C3-DF67-4E29-9771-29C2EC873B3DQ33338331-61B73595-3AC9-4331-8FA8-EFCF8E38D34CQ33342197-20896031-31E3-49B3-BA5D-B9269E2B01D8Q33343456-F7A034D2-8A61-4A2A-A0BF-6F9D6D323374Q33357487-15840F0C-1168-4F2F-8DD3-6C69639A0519Q33359877-6CD8AD10-CD29-4139-8924-99490DC006A4Q33365846-E2C0020D-382F-4FC8-B8E2-1C2919CE7C1CQ33369263-E60B7DF8-EC8A-41B6-9048-A2A175D2E23FQ33382082-8D8C8238-26E4-4442-AFDB-DB1776D920CEQ33394010-51FCB5C0-0C98-444E-9493-68F16F0733A2Q33395264-001CB942-96EA-46F7-AF51-02AE8EF541F8Q33404640-C41BDE81-ACBD-42B4-95C1-5F5DF98949DDQ33412829-0520F922-A67D-4587-942A-553BA75BF4AAQ33494314-31D48391-9F5E-4215-9B3C-AC5C048560E9Q33494653-9FE7B9B4-1282-4CC7-9AB9-D2B2C4DD8D6CQ33497617-D2173BBD-8462-46B0-A5D7-246030D733FAQ33497678-7ADDA7F8-710B-4F16-9552-E52E5091D2C6Q33598843-36E19E0A-ABFF-44DE-B045-D2B154BA100BQ33669516-2095F9B9-D291-4F17-8524-BF25493D26AFQ33991967-3CB4709F-C2EC-4DFB-A1C9-35F393CC93D3Q34119320-B6422AB5-9F18-4002-BA50-F1C0A128E12AQ34298167-D8E7A9A2-378B-47F7-8545-FEC8B6C81411Q34545082-893CD2CA-D8C4-4CF6-96B2-69633B8C4B6AQ35816742-5BD73634-616C-4615-9B57-30669A10E29AQ35892930-75BCCBE0-58A1-44F8-89B4-BF3C0C0D3CFEQ36526685-97A471B1-09B6-42F2-9C1C-89AAC32A1CC1Q42370652-B6AB3C59-9433-4EAC-B36A-8C5AC32E53B0Q43514801-CD874676-D23E-4E71-96C3-29BE49D2EEBCQ47998713-D0848BE4-BA5B-4C2B-9B0A-4B45A75BD148Q54527541-640732FA-4BC6-4478-A4CF-2D0A874DA018Q54539609-6202ECE5-7E20-4BE7-A0D9-1D728D7C7FF8Q54663019-46E3358B-EC58-414E-ADCA-0EEFDA7293E9Q55516340-C10477AB-3591-4B4B-8B16-AFFE83242333
P2860
High incidence of serum antibodies to Escherichia coli O157 lipopolysaccharide in children with hemolytic-uremic syndrome.
description
1991 nî lūn-bûn
@nan
1991 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1991 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1991年の論文
@ja
1991年論文
@yue
1991年論文
@zh-hant
1991年論文
@zh-hk
1991年論文
@zh-mo
1991年論文
@zh-tw
1991年论文
@wuu
name
High incidence of serum antibo ...... ith hemolytic-uremic syndrome.
@ast
High incidence of serum antibo ...... ith hemolytic-uremic syndrome.
@en
type
label
High incidence of serum antibo ...... ith hemolytic-uremic syndrome.
@ast
High incidence of serum antibo ...... ith hemolytic-uremic syndrome.
@en
prefLabel
High incidence of serum antibo ...... ith hemolytic-uremic syndrome.
@ast
High incidence of serum antibo ...... ith hemolytic-uremic syndrome.
@en
P2093
P921
P1476
High incidence of serum antibo ...... ith hemolytic-uremic syndrome.
@en
P2093
Heesemann J
Müller-Wiefel DE
P304
P356
10.1016/S0022-3476(05)82049-9
P407
P577
1991-09-01T00:00:00Z